By Christian Moess Laursen

GSK said it bought biopharmaceutical company Aiolos Bio for an upfront consideration of $1.0 billion and the potential for an additional $400 million, the latest in a string of pharmaceutical majors buying fast-growing biotechs to restock their pipelines.

The British pharmaceutical giant said Tuesday that the deal to buy San Francisco and London-based Aiolos Bio, which focuses on patients with respiratory and inflammatory conditions, includes a Phase 2-ready antibody called AIO-001 for the treatment of adult patients with certain respiratory and inflammatory conditions.

The portfolio addition "could expand the reach of our current respiratory biologics portfolio, to the 40% of severe asthma patients with low type 2 inflammation where treatment options are still needed," Chief Scientific Officer Tony Wood said.

The additional payment of up to $400 million is dependent on certain regulatory milestones being met, it said.

Write to Christian Moess Laursen at christian.moess@wsj.com

(END) Dow Jones Newswires

January 09, 2024 02:49 ET (07:49 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
Von Apr 2024 bis Mai 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
Von Mai 2023 bis Mai 2024 Click Here for more GSK Charts.